A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG131

Chemotherapy with cisplatin plus fluorouracil is the current standard treatment for metastatic or recurrent esophageal cancer. We have developed a 2-weekly docetaxel combined with CF regimen and conducted a Phase I/II trial for metastatic or recurrent esophageal cancer (JCOG0807). Promising efficacy and safety were shown in JCOG0807, and we have commenced a Phase III trial in September 2014 to confirm the superiority of 2-weekly DCF to CF for patients with metastatic or recurrent esophageal cancer. A total of 240 patients will be accrued from 41 Japanese institutions over a period of 4 years. The primary end point is overall survival. The secondary end points are progression-free survival, response rate and proportion of adverse events. This trial has been registered in the UMIN Clinical Trials Registry as UMIN000015107 (http://www.umin.ac.jp/ctr/index.htm).

[1]  Y. Doki,et al.  Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) , 2014, Cancer science.

[2]  K. Muro,et al.  A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) , 2014, Esophagus.

[3]  Y. Tachimori,et al.  Comprehensive Registry of Esophageal Cancer in Japan, 2004 , 2012, Esophagus.

[4]  T. Tsujinaka,et al.  Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). , 2012, Anticancer research.

[5]  Y. Doki,et al.  Multicenter Phase I/II Study of Docetaxel, Cisplatin and Fluorouracil Combination Chemotherapy in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Esophagus , 2011, Oncology.

[6]  T. Aoki,et al.  Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. , 2011, Anticancer research.

[7]  Y. Janjigian,et al.  Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). , 2010 .

[8]  J. Ajani,et al.  Weekly docetaxel, cisplatin, and 5‐fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer , 2010, Cancer.

[9]  M. Stockler,et al.  Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial , 2010, British Journal of Cancer.

[10]  Y. Shinomura,et al.  Phase I/II Study of Docetaxel/Cisplatin/Fluorouracil Combination Chemotherapy Against Metastatic Esophageal Squamous Cell Carcinoma , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  F. Lordick,et al.  Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[13]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[14]  L. Rybak.  Mechanisms of cisplatin ototoxicity and progress in otoprotection , 2007, Current opinion in otolaryngology & head and neck surgery.

[15]  J. Schellens,et al.  Relationship between cisplatin administration and the development of ototoxicity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  H. Yamana,et al.  Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.

[17]  L. Collette,et al.  Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. , 1997, European journal of cancer.

[18]  H. Watanabe,et al.  Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. , 1992, Japanese journal of clinical oncology.

[19]  H. Watanabe,et al.  Phase II evaluation of combined cisplatin and vindesine in advanced squamous cell carcinoma of the esophagus: Japanese Esophageal Oncology Group Trial. , 1991, Japanese journal of clinical oncology.

[20]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[21]  D. Schoenfeld,et al.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. , 1982, Biometrics.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  Japanese Society of Esophageal Diseases.  Comprehensive registry of esophageal cancer in Japan, 1999 , 2005, Esophagus.

[24]  P. Enzinger,et al.  Esophageal cancer. , 2003, The New England journal of medicine.

[25]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.